SAN DIEGO, July 05, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds…
Chicago (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von William Blair & Co:
Die Investmentbank William Blair & Co habe in einer aktuellen Studie…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Goldman Sachs:
Folge man den Analysten von Goldman Sachs, dann könnte die Aktie von…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Mizuho Securities USA:
Die Analysten von Mizuho Securities USA stufen die Aktie von Sarepta…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von TD Cowen:
Die Analysten von TD Cowen senken das Rating für die Aktie von…
London (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Barclays:
Die britische Investmentbank Barclays habe ihr Kursziel für die Aktie von Sarepta Therapeutics Inc.…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Wolfe Research:
Die Analysten von Wolfe Research haben am Vorabend die Bewertung der Aktie…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Jefferies & Co:
Der Analyst Andrew Tsai von der Investmentbank Jefferies & Co habe…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Morgan Stanley:
Die US-Investmentbank Morgan Stanley habe in einer aktuellen Studie die Aktie von…
These are some of the stocks posting the largest moves in early trading Monday.…
Minneapolis (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Piper Sandler:
Das Biotech-Unternehmen Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH, Ticker-Symbol: AB3A, NASDAQ-Symbol: SRPT)…
…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von H.C. Wainwright & Co:
Die Analysten von H.C. Wainwright & Co stufen die Aktie…
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged almost 45% after the company disclosed the death of a second patient from acute…
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Kalte Dusche für die Aktionäre von Sarepta Therapeutics am gestrigen Dienstag. Auf der einen Seite belastet das Papier die umstrittene…
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2025,…
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -1,077.14% and 6.68%, respectively, for the quarter ended March 2025. Do…
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of …
Sarepta Therapeutics (SRPT) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year,…
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The companys…
Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Scotiabank:
Rating und Kursziel
Scotiabank senkt das Kursziel für die Aktie von Sarepta Therapeutics Inc. (ISIN:…
Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest…
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has…
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has…
…
SRPT earnings call for the period ending December 31, 2024.…
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -19.79% and 2.83%, respectively, for the quarter ended December 2024. Do…
Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This…
The heavy selling pressure might have exhausted for Sarepta Therapeutics (SRPT) as it is technically in oversold territory now. In…
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in…
…
Sarepta Therapeutics SWOT analysis: DMD leaders stock poised for growth…
Minneapolis (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Piper Sandler:
1. Neue Bewertung und Kurszielsetzung
Piper Sandler hat das Kursziel für die Aktie von…
Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von BMO Capital Markets:
Aktuelle Bewertung
Die Analysten von BMO Capital Markets stufen die Aktie von Sarepta…
Charlotte (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von BofA Securities:
Rating und Kursziel
BofA hat das Kursziel für die Aktie von Sarepta Therapeutics Inc.…
Boston, MA (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Leerink Partners:
Aktuelle Bewertung
Die Analysten von Leerink Partners stufen die Aktie von Sarepta Therapeutics…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von J.P. Morgan Securities:
JPMorgan sieht die jüngste Schwäche der Aktie von Sarepta Therapeutics Inc.…
…
SRPT earnings call for the period ending September 30, 2024.…
…
These two could become direct competitors relatively soon.…
SRPT earnings call for the period ending June 30, 2024.…
Sarepta Therapeutics falls on revenue miss, weak outlook…
One companys negative results can increase scrutiny of anothers work.…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von der Citigroup:
Die Analysten der Citigroup stufen die Aktie des Biopharma-Unternehmens Sarepta Therapeutics Inc.…